2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1829

Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling
Abstract Number: 1830

Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors
Abstract Number: 1831

Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus
Abstract Number: 1832

Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies
Abstract Number: 1833

Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Abstract Number: 1834

Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
Abstract Number: 1835

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
Abstract Number: 1836

Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 1837

Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
Abstract Number: 1838

Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study
Abstract Number: 1839

Safety and Immunogenicity of Quadrivalent Human Papilloma Virus (qHPV) Vaccine (Gardasil®) in Systemic Lupus Erythematous (SLE), Phase I Trial Completion
Abstract Number: 1840

How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?
Abstract Number: 1841

Meningitis in Systemic Lupus Erythematosus Patients: Epidemiologic Profile of Listeria Monocytogenes Infection. a Single-Center Study
Abstract Number: 1842

Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique
Abstract Number: 1843

Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].